Skip to main content
Top
Literature
6.
go back to reference Periprocedural Management of Anticoagulation Writing Committee JU, Doherty JU, Gluckman TJ, et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017. https://doi.org/10.1016/j.jacc.2016.11.024 Periprocedural Management of Anticoagulation Writing Committee JU, Doherty JU, Gluckman TJ, et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017. https://​doi.​org/​10.​1016/​j.​jacc.​2016.​11.​024
Metadata
Title
Cost-Effectiveness of Bridging Anticoagulation
Author
Matthew A. Pappas, MD, MPH
Publication date
01-01-2021
Publisher
Springer International Publishing
Keywords
Stroke
Heparin
Published in
Journal of General Internal Medicine / Issue 1/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05322-x

Other articles of this Issue 1/2021

Journal of General Internal Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine